Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001140361-26-031060
Filing Date
2026-08-04
Accepted
2026-08-04 08:30:18
Documents
1
X0202

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 6035
  Complete submission text file 0001140361-26-031060.txt   7627
Mailing Address 4960 PEACHTREE INDUSTRIAL BOULEVARD SUITE 240 NORCROSS GA 30071
Business Address 4960 PEACHTREE INDUSTRIAL BOULEVARD SUITE 240 NORCROSS GA 30071 678-620-3186
GALECTIN THERAPEUTICS INC (Subject) CIK: 0001133416 (see all company filings)

EIN.: 043562325 | State of Incorp.: NV | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-77935 | Film No.: 261235648
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 12575 ULINE DRIVE PLEASANT PRAIRIE WI 53158
Business Address
Uihlein Richard E (Filed by) CIK: 0001694903 (see all company filings)

Type: SCHEDULE 13D/A